asbestos lawyers - Worthington & Caron, PC

Over $2.5 billion

obtained for mesothelioma patients & families

In The News

Recent Study Confirms Effectiveness of Radiation Therapy Following Lung-Sparing Pleurectomy/Decortication Surgery

01-09-2014

There has been a long-standing debate over which surgery is more effective for treating malignant pleural mesothelioma (MPM). For many years, a majority of surgeons believed that a radical procedure called Extrapleural Pneumonectomy (EPP), which involves removal of the mesothelioma tumor along with the affected lung, diaphragm and pericardium, was the preferred way of surgically treating MPM.

However, in recent years, many surgeons have come to the realization that the Pleurectomy/Decortication (P/D) procedure innovated by UCLA and West Los Angeles VA Medical Center Thoracic Surgeon Dr. Robert Cameron, in which the tumor is removed and the patient is left with a functioning lung, is the more effective and less risky procedure.

For the surgeons that continue to perform EPP despite the mounting studies confirming the effectiveness of lung-sparing P/D, one of the reasons they cite to is the purported inability to effectively deliver radiation to the area following P/D.

The typical protocol following both EPP and P/D is to have patients undergo a series of radiation treatments, typically 25, beginning a month or so after the surgery. The purpose of the radiation treatments is to eradicate the microscopic tumor cells that remain after all visible tumor is removed. It has been the belief of EPP proponents that radiation treatments following P/D are much less effective because of the presence of the lung and related tissues.

A study published in the November edition of the international journal Lung Cancer disproves this theory. Researchers at the Centro di Riferimento Oncologico di Aviano in northern Italy monitored 20 patients with malignant pleural mesothelioma who were given localized high dose radiation therapy following P/D surgery. The patients underwent 25 radiation treatments likely over the course of five weeks. The survival rate in the study was 70 percent at two years and 49 percent at three years or more, with a median survival rate of 33 months. The estimated progression-free survival rate was 68 percent at two years and 46 percent at three years.

The results of this study confirm what proponents of P/D have believed for some time, namely that it is possible to deliver full dose radiation following lung-sparing surgery.

Categories: Treatment Options

Get Empowered

We put your medical and personal needs first and provide compassionate representation.

Speak with an Attorney